Experimental Hematology
Volume 35, Issue 12 , Pages 1766-1776 , December 2007

Vectors selected from adeno-associated viral display peptide libraries for leukemia cell–targeted cytotoxic gene therapy

  • Stefan Michelfelder

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • ,
  • Mi-Kyung Lee

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • ,
  • Elisethe deLima-Hahn

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • ,
  • Thomas Wilmes

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • ,
  • Felix Kaul

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • ,
  • Oliver Müller

      Affiliations

    • Deutsches Krebsforschungszentrum, Heidelberg, Germany
    • ,
  • Jürgen A. Kleinschmidt

      Affiliations

    • Deutsches Krebsforschungszentrum, Heidelberg, Germany
    • ,
  • Martin Trepel

      Affiliations

    • Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    • Institute for Molecular Medicine and Cell Research, University of Freiburg Medical Center, Freiburg, Germany
    • Corresponding Author InformationOffprint requests to: Martin Trepel, M.D., Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, D-79106 Freiburg, Germany

Received 8 May 2007 ,Revised 17 July 2007 ,Accepted 23 July 2007.

References 

  1. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Prog.). 2004;2004:98–117
  2. Ponnazhagan S, Wang XS, Woody MJ, et al. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J Gen Virol. 1996;77(Pt 6):1111–1122
  3. Ponnazhagan S, Mahendra G, Kumar S, Thompson J, Castillas JMJ. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol. 2002;76:12900–12907
  4. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab ‘gamma)(2) antibody. Nat Biotechnol. 1999;17:181–186
  5. Ried MU, Girod A, Leike K, Buning H, Hallek M. Adeno-associated virus capsids displaying immunoglobulin- binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol. 2002;76:4559–4566
  6. Perabo L, Buning H, Kofler DM, et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther. 2003;8:151–157
  7. Beck C, Uramoto H, Boren J, Akyurek LM. Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther. 2004;4:457–467
  8. Trepel M, Grifman M, Weitzman MD, Pasqualini R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Human Gene Ther. 2000;11:1971–1981
  9. Baker AH. Targeting AAV vectors. Mol Ther. 2003;7:433–434
  10. Büning H, Ried MU, Perabo L, et al. Receptor targeting of adeno-associated virus vectors. Gene Ther. 2003;10:1142–1151
  11. Muzyczka N, Warrington KH. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther. 2005;16:408–416
  12. Nielsen PE. Systemic delivery: the last hurdle?. Gene Ther. 2005;12:956–957
  13. Trepel M, Arap W, Pasqualini R. Exploring vascular heterogeneity for gene therapy targeting. Gene Ther. 2000;7:2059–2060
  14. Monahan PE, Joos K, Sands MS. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Exp Opin Drug Saf. 2002;1:79–91
  15. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003;3:545–565
  16. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat Med. 1999;5:1052–1056
  17. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 2001;3:964–975
  18. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 2003;7:515–525
  19. Müller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003;21:1040–1046
  20. Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther. 2003;10:1551–1558
  21. Work LM, Nicklin SA, Brain NJR, et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther. 2004;9:198–208
  22. White SJ, Nicklin SA, Buning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109:513
  23. Shi W, Hemminki A, Bartlett JS. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol. 2006;103:1054–1062
  24. Shi X, Fang G, Shi W, Bartlett JS. Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum Gene Ther. 2006;17:353–361
  25. Rabinowitz JE, Xiao WD, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology. 1999;265:274–285
  26. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol. 2000;74:8635–8647
  27. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther. 2001;12:1697–1711
  28. Warrington KH, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol. 2004;78:6595–6609
  29. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther. 2001;4:174–181
  30. Work LM, Buning H, Hunt E, et al. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther. 2006;13:683–693
  31. Opie SR, Warrington KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol. 2003;77:6995–7006
  32. Kern A, Schmidt K, Leder C, et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol. 2003;77:11072–11081
  33. Waterkamp DA, Müller OJ, Ying Y, Trepel M, Kleinschmidt JA. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med. 2006;8:1307–1319
  34. Perabo L, Goldnau D, White K, et al. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol. 2006;80:7265–7269
  35. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and purification of recombinant adeno-associated virus. Methods Enzymol. 2000;316:743–761
  36. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 1987;61:3096–3101
  37. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224–2234
  38. Grimm D, Kern A, Pawlita M, Ferrari FK, Samulski RJ, Kleinschmidt JA. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 1999;6:1322–1330
  39. Rohr UP, Heyd F, Neukirchen J, et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods. 2005;127:40–45
  40. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol. 1997;71:5236–5243
  41. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646–4654
  42. Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006;125:385–398
  43. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72:1438–1445
  44. Lidholt K, Weinke JL, Kiser CS, et al. A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci U S A. 1992;89:2267–2271
  45. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61:3022–3026
  46. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther. 2004;4:357–372
  47. Blankinship MJ, Gregorevic P, Allen JM, et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 2004;10:671–678
  48. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23:321–328
  49. Sumner-Jones SG, Davies LA, Varathalingam A, Gill DR, Hyde SC. Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways. Gene Ther. 2006;13:1703–1713
  50. Bupp K, Roth MJ. Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther. 2003;14:1557–1564
  51. Huttner NA, Girod A, Perabo L, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 2003;10:2139–2147
  52. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med. 1999;5:78–82
  53. Qing K, Mah C, Hansen J, Zhou SZ, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. 1999;5:71–77
  54. Kashiwakura Y, Tamayose K, Iwabuchi K, et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol. 2005;79:609–614
  55. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006;80:9831–9836

 Stephen Michelfelder and Mi-Kyung Lee contributed equally to this work.

PII: S0301-472X(07)00494-8

doi: 10.1016/j.exphem.2007.07.018

Experimental Hematology
Volume 35, Issue 12 , Pages 1766-1776 , December 2007

Article Tools

* Image Usage & Resolution